Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer

Trial ID # NCT00281632
Phase II
Drug Class Angiogenesis Inhibitors: Multi-targeted RTK
Drug Name Pazopanib
Alternate Drug Names Votrient
Drugs in Trial Pazopanib
Eligible Participant

Recurrent ovarian cancer (after CR to first-line platinum-based therapy)

Patients Enrolled

36; 27 Pt-S, 6 Pt-R, 3 Pt-Rf

Therapy Setting


Study Design



ORR, evaluated per RECIST or CA125


ORR: 17.6% (3PR, n=17, RECIST)
ORR: 31% (CA125)

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: elevated liver enzymes (8%) and edema (1 patient)


Promising activity of single agent pazopanib


Friedlander M et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol (2010) 119(1):32 -7

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.